Janux Therapeutics (JANX) Total Liabilities (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Total Liabilities data on file, last reported at $86.7 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 126.33% year-over-year to $86.7 million in Q1 2026; TTM through Mar 2026 was $86.7 million, a 126.33% increase from a year earlier, with the FY2025 full-year figure at $44.7 million, up 15.51% from the prior year.
• Total Liabilities for Q1 2026 stood at $86.7 million, up from $44.7 million in the prior quarter.
• Over the last five years, Total Liabilities for JANX reached as high as $86.7 million in Q1 2026 and fell as low as $12.5 million in Q1 2022.
• Historically, Total Liabilities has averaged $41.4 million across 5 years, with a median of $41.6 million in 2022.
• Across the five-year window, Total Liabilities jumped 245.45% in 2022 and dropped 20.32% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $43.3 million in 2022, then decreased by 16.67% to $36.1 million in 2023, then rose by 7.42% to $38.7 million in 2024, then gained by 15.51% to $44.7 million in 2025, then jumped by 93.75% to $86.7 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $86.7 million in Q1 2026, $44.7 million in Q4 2025, and $48.2 million in Q3 2025.